Objective: Dysferlinopathies are a family of untreatable muscle disorders caused by mutations in the dysferlin gene. Lack of dysferlin protein results in progressive dystrophy with chronic muscle fiber loss, inflammation, fat replacement, and fibrosis; leading to deteriorating muscle weakness. The objective of this work is to demonstrate efficient and safe restoration of dysferlin expression following gene therapy treatment. Methods: Traditional gene therapy is restricted by the packaging capacity limit of adeno-associated virus (AAV), however, use of a dual vector strategy allows for delivery of over-sized genes, including dysferlin. The two vector system (AAV.DYSF.DV) packages the dysferlin cDNA utilizing AAV serotype rh.74 through the use of two discrete vectors defined by a 1 kb region of homology. Delivery of AAV.DYSF.DV via intramuscular and vascular delivery routes in dysferlin deficient mice and nonhuman primates was compared for efficiency and safety. Results: Treated muscles were tested for dysferlin expression, overall muscle histology, and ability to repair following injury. High levels of dysferlin overexpression was shown for all muscle groups treated as well as restoration of functional outcome measures (membrane repair ability and diaphragm specific force) to wild-type levels. In primates, strong dysferlin expression was demonstrated with no safety concerns. Interpretation: Treated muscles showed high levels of dysferlin expression with functional restoration with no evidence of toxicity or immune response providing proof of principle for translation to dysferlinopathy patients.
Introduction
Dysferlinopathies are a family of disorders caused by autosomal recessive mutations in the dysferlin (DYSF) gene. These disorders include limb girdle muscular dystrophy type 2B (LGMD2B), 1 Miyoshi Myopathy (MM1), 2 and distal anterior compartment myopathy, [3] [4] [5] among others. [1] [2] [3] 6 LGMDs comprise 30% of all progressive muscular dystrophies with LGMD2B as the most frequently diagnosed dysferlinopathy. 7, 8 Mutations in DYSF lead to a progressive muscular dystrophy with chronic muscle fiber loss, inflammation, fat replacement, and fibrosis, all contributing to deteriorating weakness. 7 In general, patients present with an abrupt onset in the second decade with progressive involvement of proximal and distal musculature. 9, 10 Although dysferlinopathies are slowly progressing disorders, approximately one-third of patients become wheelchair-dependent within 15 years of disease onset. 7, 10 There is no cure for these diseases and limited treatment options are available. Even use of steroids, which have been previously successful for Duchenne muscular dystrophy patients, is ineffective and not warranted. 11 Although it has been occasionally reported that treatment with IV-IG or rituximab therapies can be effective by modifying the immune response, to date there remains no cure. 12, 13 Thus, the need for a treatment is clear. The DYSF gene consists of 55 exons encompassing 150 kb of genomic DNA. 14 The associated cDNA is 6.5 kb and codes for the dysferlin protein. 2, [14] [15] [16] Dysferlin, a member of the ferlin family, is composed of seven N-terminal C2 domains with a transmembrane C-terminus. 17, 18 Dysferlin has multiple roles in skeletal muscle including sarcolemmal membrane repair, 16, 19, 20 vesicle trafficking, 21 t-tubule structure and function 22 and endocytosis. 23 Our group 16 and others 19, 20, 24 have studied the role of dysferlin in Ca 2+ -dependent membrane repair, consistently reporting a decrease in dysferlin-deficient fiber sarcolemmal resealing following acute injury. As skeletal muscle is mechanically active, this deficit in repair leads to regeneration/degeneration of fibers with muscle fiber necrosis/loss, and progressive limb weakness. 19, 20 Recent years have shown profound development of adeno-associated viral (AAV) gene transfer. 16, [25] [26] [27] [28] Although there was some reported plasticity, 29, 30 the packaging limit of AAV is 4.7 kb, requiring the development of cDNA cassettes within this constraint. Groups have reported the use of miniaturized genes and transsplicing approaches; however, reduced gene expression and protein function hinder the technology. [31] [32] [33] [34] In our previous work, we delivered full-length DYSF using AAV5 delivery of partially packaged 5 0 and 3 0 fragments of the dysferlin containing expression cassette. 16 Southern blot revealed that all encapsidated DNA was ≤~5.2 kb in length. 16 Overlapping homologous sequences facilitated reconstitution of full-length DYSF. As the packaging in AAV5 was uncontrolled, it became desirable to develop a strategy for packaging of discrete, well-identified constructs. From our experience and that of others, 16, 35, 36 we used a dual vector strategy using co-injection of two vectors.
To accomplish efficient gene expression, we split the dysferlin cDNA into two segments with a 1 kb overlap region and packaged them into separate cassettes within AAVrh.74. Upon co-injection, the two cDNA segments provide a substrate for homologous recombination or repair 29, 37, 38 to recover the full-length gene. In our studies, the dual vector strategy demonstrates higher levels of gene expression than previous work with AAV5.DYSF. 16 In addition, membrane repair capacity and diaphragm specific force in the dysferlin knock-out mouse model were restored to wild-type (WT) levels. Following demonstration of robust dysferlin expression in mice we performed injections in rhesus macaques (nonhuman primates [NHPs] ) to validate a safety profile for the dual vector treatment. 39 We found no toxicity following AAVrh74.DYSF.DV in NHPs. Taken together with functional outcome measures in dysferlin deficient mice, AAVrh.74.DYSF.DV is well-positioned for translation to dysferlinopathy patients.
Materials and Methods

Dysferlin gene construction
For all gene transfer studies, human dysferlin cDNA (Genbank# NM_003494.3) was used. The full-length dysferlin cassette was made as previously described. 16 The dual vector dysferlin cassettes were generated to encompass the 5 0 or the 3 0 portion of the full-length dysferlin cassette. 16 The 5 0 cassette contains the MHCK7 promoter, the chimeric intron and the first 3370 bp of the dysferlin cDNA flanked by AAV2 ITRs. The 5 0 plasmid, pAAV.MHCK7.DYSF5 0 .PTG, was generated through a NotI restriction enzyme digest on the original pAAV.MHCK7.DYSF plasmid, removing the entire dysferlin cDNA. The 5 0 portion of the dysferlin cDNA was then polymerase chain reaction (PCR) amplified using the primers 5 0 F -TGCGGAATTGTACCCGCGGCCGCGGC-TAGCCACCAT and 5 0 R -TAAAGATCTTTTATTGCGG-CCGCCCTCAAGGGCAAACACAGCTG and then cloned into the NotI digested vector using the ClonEZ PCR Cloning kit (Genscript Piscataway, NJ USA), forming the plasmid pAAV.5 0 DYSF. Both constructs were fully sequenced to confirm plasmid fidelity. For gene transfer studies in NHPs, the 5 0 vector genome (vg) includes a FLAG tag after the Kozak sequence and before the start of the dysferlin 5 0 cDNA. The FLAG tag is used for differentiation of endogenous and delivered dysferlin.
The 3 0 vector, pAAV.DYSF3 0 .POLYA, was generated by performing a PmeI/Tth111I double restriction enzyme digest on pAAV.MHCK7.DYSF which removed the entire promoter, chimeric intron, and 2407 bp of the 5 0 portion of the dysferlin cDNA from the vector. The remaining vector was end-repaired and ligated to form the plasmid containing the remaining 3866 bp of the dysferlin cDNA also including the native 3 0 UTR/polyA sequence. Sequencing was performed to confirm the removal of the 5 0 portion of the dysferlin cassette.
AAV vector production pAAV.MHCK7.DYSF was packaged into AAV serotype 5 as previously described. 16 pAAV.MHCK7.DYSF5 0 .PTG and pAAV.DYSF3 0 .PolyA were packaged into AAV serotype Rh74 capsid using the standard triple transfection protocol. 16 A quantitative PCR-based titration method was used to determine an encapsulated vg titer utilizing a Prism 7500 Fast Taqman detector system (PE Applied Biosystems Grand Island, NY USA). 40 The following primers/probes were used: AAVrh.74.MHCK7.DYSF5
0 . PTG -F primer -CCAACACCTGCTGCCTCTAAA, R primer -GTCCCCCACAGCCTTGTTC, Probe -TGGA TCCCCTGCATGCGAAGATC; AAVrh.74.DYSF3
0 .PolyA -F primer -AGATCACCCCACTTCCATCATT, R primer -TGAAATATGTCTGAGCTGATCCAAA, Probe -CCTT CTCCCCCAACCCAACGCT. For studies in NHPs (n = 3), the left TA was injected with 5 9 10 12 vg total dose of AAVrh.74.DYSF.DV. Right TA was used as a contralateral control and was injected with normal saline.
Animal models
Regional vascular delivery
129-Dysf KO mice at 4-6 weeks of age were perfused with 1 9 10 12 vg AAVrh.74.MHCK7.DYSF5 0 .PTG and 1 9 10 12 vg AAVrh.74.DYSF3 0 .PolyA (total dose 2 9 10 12 vg in 100 lL normal saline) as previously described. 41 Briefly, mice were anesthetized and the femoral bundle was visualized via a small incision proximal to the mid-thigh. Arterial blood flow was controlled by catheter placement using a customized heat pulled polypropylene 10 (PE-10) catheter. Prior to vector administration, the arterial catheter was flushed (preflush) with 100 lL sterile normal saline. Immediately prior to vector administration all blood flow to the extremity was impeded (isolated limb perfusion -ILP) by tightening the ligature at the mid-thigh. AAVrh.74.DYSF.DV was perfused through the femoral artery in 100 lL administered at a rate of~2 lL per second (over 60-80 sec). After 10 min of maintained vascular occlusion, 100 lL of normal saline was administered to the arterial catheter (again at about 2 lL per second) as a postflush and the tourniquet was then released. The wound was flushed with sterile normal saline and closed with a 6-0 proline suture. Four weeks postinjection, animals (n = 4) were sacrificed and muscles (TA, gastrocnemius, EDL) were extracted for analysis of dysferlin expression. AAVrh.74.DYSF3 0 .PolyA, total volume of 150 lL) into 8 week old Bla/J mice (n = 6 per dose). Mice were sacrificed 12 weeks postinjection with a full necropsy performed. The diaphragm was subjected to force measurements (see below), the FDB was tested for membrane repair ability and muscles and organs were harvested for expression and histopathology.
Systemic delivery
For histological analysis all muscles and organs (unless used for membrane repair) were embedded in 7% gum tragacanth and flash frozen in liquid nitrogen cooled isopentane. Frozen sections (12 lm) were collected for immunohistochemistry and western blot analysis.
Membrane repair assay
The ability of muscle membrane to repair following injury was assessed on muscle fibers isolated from FDB muscles using treatment with a 2% collagenase Type I solution. 
Diaphragm tetanic contraction
As an additional outcome measure to the membrane repair assay, the diaphragms of systemically treated Bla/J mice were assessed at 20 weeks of age (n = 6 per dose). Mice were euthanized and the diaphragm was dissected with rib attachments and central tendon intact, and placed in K-H buffer at 37°C as previously described. 42 ,43 A 1-2 mm wide section (length from rib to tendon) of diaphragm was isolated and attached to a force transducer. The diaphragm strip was looped around a basket assembly attached to the transducer and the tendon was pierced by a pin. The muscle was stretched to optimal length for measurement of twitch contractions, and then allowed to rest for 10 min before initiation of the tetanic protocol. The tetanic protocol consists of a series of six tetanic contractions (20, 50, 80, 120, 150, 180 Hz) occurring at 2 min intervals, each with duration of 250 msec. The force was recorded for each stimulus and normalized for muscle width and length.
Immunohistochemistry
Immunolabeling for dysferlin was performed on all transduced tissue to assess efficacy of gene transfer. For dysferlin detection, tissue sections (12 lm) were incubated with rabbit anti-human dysferlin monoclonal antibody (Romeo; Epitomics, Abcam Burlingame, CA USA) at 1:100 in blocking solution (10% goat serum, 0.1% Tween-20 in PBS) for 1 h at 25°C in a wet chamber. Sections were washed with PBS 3 9 20 min, reblocked, and then incubated for 45 min at 25°C with an Alexa 568 goat anti-rabbit antibody (Molecular Probes, Grand Island, NY USA) at a 1:250 dilution. Sections were washed in PBS for 3 9 20 min and mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA USA). Images were captured with a Zeiss Axioskop2 Plus Microscope and Axiocam MRC5 camera (Zeiss, Thornwood, NY USA). Four random 209 images (each field with an average of 150 muscle fibers) were captured per muscle and the number of fibers with dysferlin labeling was counted and expressed as percent of total number of fibers.
Morphometrics
Centralized nuclei counts were performed on sections of muscle stained with hematoxylin and eosin (H&E) from treated animals. Four random 209 fields of 12 lm sections for each muscle were captured and the number of fibers with central nuclei counted and expressed as a percentage of the total number of fibers. Two-way analysis of variance (ANOVA) statistical analysis was performed to compare treatment effect on central nucleation (P < 0.01).
Western blot analysis
From each muscle, fresh-frozen serial tissue sections were taken for protein preparation. Muscle samples harvested from treated and control groups were compared with WT tissue for levels of vector-mediated dysferlin compared to endogenous dysferlin. Protein (15 lg) extracted from treated and control samples was separated by sodiumdodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (3-8% Novex NuPAGE gradient gels, Invitrogen), blotted on PVDF (polyvinylidene fluoride) or nitrocellulose membrane and probed with NCL-Hamlet (Novocastra, Buffalo Grove, IL USA) primary antibody (for dysferlin) at a dilution of 1:1000, or c-tubulin antibody (Sigma-Aldrich, St. Louis, MO USA) at a dilution of 1:10,000 followed by horseradish-peroxidase (HRP) labeled goat anti-mouse IgG (1:5000; Millipore, Billerica, MA USA) or goat anti-rabbit IgG (1:5000; Millipore) and signal captured on Hyblot CL autoradiography film (Denville, Metuchen, NJ USA). Densitometry analysis was performed using ImageQuant TL (GE Healthcare Life Sciences, Pittsburgh, PA, USA).
Immunological assays
For NHPs, whole blood samples were collected biweekly and used for ELISA and enzyme-linked immunosorbent spot assay (ELISpot) to track immunological response to the viral capsid, AAVrh.74, and the dysferlin transgene product. ELISAs were performed in 96-well Nunc Maxisorb ELISA plates coated with 2 9 10 9 vg AAVrh.74 per well in carbonate buffer. Serum samples were diluted from 1:5 through 1:819,200 in blocking solution (5% nonfat dry milk, 1% normal goat serum [Invitrogen] in PBS À/À ) and added to wells for 1 h at room temperature. Sera from previously screened NHPs were used for controls. Goat anti-monkey IgG-HRP (Sigma) was used as the secondary antibody for 30 min at room temperature followed by exposure with Ultra TMB-ELISA solution (Thermo Scientific, Waltham, MA USA). Absorbance of wells at OD450 was measured and used to calculate titer of positive reaction.
Peripheral blood mononuclear cells (PBMCs) were separated from whole blood samples through density gradient centrifugation, as previously described. 44 Briefly, fresh blood samples are spun in a table-top centrifuge (Sorval Legend RT, Thermo Scientific) and the top plasma layer is removed and stored in À80°C freezer. The remaining blood was mixed with PBS À/À (Invitrogen), underlayed with Ficoll-Paque (Fisher Scientific, Pittsburgh, PA USA) and spun for density gradient separation. The middle layer containing the PBMCs is then removed and subjected to various wash/spin cycles before a final resuspension in CellGro RPMI1640 media (Fisher) supplemented with 10% fetal calf serum (Fisher) and penicillin and streptomycin. PBMCs were then plated in IP filter plates (Millipore) at a density of 2 9 10 5 cells/well. IP plate wells were precoated with monoclonal antibody provided in monkey interferon-c ELISpot kit (U-Cytech Biosciences, Utrecht, The Netherlands). Three peptide pools were used which were used for the AAVrh.74 capsid protein (Genemed Synthesis, San Antonio, TX) containing 34-36 peptides, each 18 amino acids long and overlapping by 11 residues. Ten peptide pools were used which encompass the dysferlin protein (Genemed Synthesis) containing 48 peptides, each 15 amino acids long and overlapping by 10 residues. Concanavalin A (Sigma) served as a positive control and 0.25% dimethylsulfoxide as a negative control. Peptides were added directly to the wells at a final concentration of 1 lg/mL. After the addition of PBMCs and peptides, the plate was incubated at 37°C in 5-7% CO 2 and 100% humidity for 36-48 h. Following incubation the plate was developed according to the manufacturer's protocol. Interferon-c spot formation was counted using Immunospot software (Series 3B Analyzer; Cellular Technology, Ltd, Cleveland, OH).
Blood samples from the NHPs were analyzed monthly for chemistry panel and complete blood count (CBC) testing internally.
Results
AAVrh.74.Dysferlin.DV
We constructed a human dysferlin dual vector cassette driven by the muscle specific MHCK7 promoter ( Fig. 1 ) with a chimeric intron included for augmented RNA processing. The dysferlin cDNA was divided into two discrete vectors containing either the 3 0 or 5 0 ends. The 5 0 cassette contains the MHCK7 promoter, chimeric intron and the first 3370 bp of the dysferlin cDNA, while the 3 0 cassette contains the end 3866 bp of the dysferlin cDNA and the native 3 0 UTR/polyadenylation sequence. Importantly, the two vectors contain a 1 kb overlap region in the dysferlin cDNA to facilitate recombination in vivo. The individual cassettes were packaged into an AAVrh.74 vector using standard transfection and purified. Both vectors were within the 4.7 kb packaging limit of AAV and full-length dysferlin protein was detected in skeletal muscle consistent with the proposed process of homologous recombi- Fig. S1 ). Western blot analysis showed a single, well-defined band at 237 kDa for the full-length protein at all-time points (Fig.  S1 ).
As a direct comparison to AAV5.MHCK7.DYSF, we tested the ability of the AAVrh.74.DYSF.DV vectors to effectively transduce muscle fibers and express full-length dysferlin protein, we performed IM injections into the TA muscle of 4-6 week old 129-Dysf À/À at 2 9 10 11 vg dose (1 9 10 11 vg of each vector). Animals were sacrificed 1, 3, and 6 months postinjection and muscle sections were immunolabeled with anti-human dysferlin antibody and assessed for histopathological changes. As previously reported, Dysf
À/À mice demonstrate mild pathology at young ages seen primarily in small numbers of centrally nucleated fibers and isolated necrotic fibers. 19, 45 Following gene transfer with AAVrh.74.-DYSF.DV there was no evidence of toxicity in the treated muscles ( Fig. 2A) . Widespread dysferlin expression localized to the sarcolemma was detected through immunofluorescence and western blot of the treated TA tissue with no detectable dysferlin expression in contralateral control muscles (Fig. 2A) . Quantification of muscle fibers expressing dysferlin at 1, 3, and 6 month demonstrated high levels of expression (74 AE 8.5%, 75.7 AE 4.9% and 90.5 AE 1.5%, respectively; Table 1 ). This expression was an improvement as compared to our values using AAV5.DYSF (Table 1) . 16 Western blot analysis showed a well-defined 237 kDa band for treated muscles which was absent for PBS control-treated animals (Fig. 2B) . Densitometry analysis of the western blot normalized to c-tubulin shows expression of dysferlin through dual vector at 86.8 AE 1.7% in comparison to wild type. This is an improvement over our previously published expression of dysferlin using AAV5 (69.1 AE 19%). 16 Additionally, TAs samples injected with AAVrh.74.DYSF5 0 .PTG, AAVrh.74.DYSF3 0 .PolyA, or AAVrh.74.DYSF.DV were screened for dysferlin protein production through western blot (Fig. S2) . Importantly, no dysferlin protein (full-length or truncated) was detectable unless both the 5 0 and 3 0 viral preps were codelivered. This was also extensively studied through RNA analysis in our previous work with AAV5.-DYSF. 16 Following necropsy at 3 or 6 months, the left and right TA along with organs (heart, lung, liver, kidney, spleen, and gonad) were harvested and analyzed for biodistribution of vgs. High levels of viral vector were detected in the left TA (treated) as expected; however, detectable levels were also found in all tissues tested ( Fig. 2C and D) . Importantly, western blotting of tissue lysates only found dysferlin protein expression in the injected left TA (not shown).
Regional vascular delivery
Given the robust expression of dysferlin upon IM delivery, we next tested the ability of the vectors to cross the vascular barrier and transduce muscle through an ILP procedure. We have previously shown that the rh.74 transduces muscle very efficiently when delivered through the vasculature. 25 This lays the foundation for future translation to clinical practice as it allows for treatment of multiple muscle groups. The lower left limb of 4-6 week old Dysf À/À mice was perfused with 2 9 10 12 vg AAVrh.74.DYSF.DV (1 9 10 12 vg of each vector) in 100 lL normal saline as previously described. 41 Animals were sacrificed 4 weeks postinjection to study dysferlin expression. Quantification of transduced muscles showed 68 AE 15% of fibers expressing dysferlin throughout the lower limb muscles (TA and gastrocnemius, Fig. 3 ).
Systemic vascular delivery
To test the feasibility and effectiveness of systemic delivery approach, we treated BlaJ (B.6A-Dysf prmd /GeneJ, dysferlin deficient) mice with saline, 2 9 10 12 vg, or 6 9 10 12 vg total dose of AAVrh.74.DYSF.DV through tail vein injections. Animals were sacrificed at 3 months and analysis included diaphragm specific force measurements, membrane repair analysis in the FDB muscle and full necropsies to quantify dysferlin expression and assess histopathology. Quantification of muscle fibers expressing dysferlin was performed in the TA, gastrocnemius, quadriceps, triceps, and diaphragm muscles. At 2 9 10 12 vg, the muscles exhibited low level, variable expression, while the 6 9 10 12 vg dose demonstrated widespread expression in all muscles (Table 2, Fig. 4) . Whereas untreated BlaJ mice exhibit low levels of pathology at the time point studied, significant differences in fibers with centralized nuclei were calculated for the gastrocnemius muscle for both low and high dose treated animals. Diaphragm central nuclei counts for both doses were not significantly different from WT BL6 mice (Fig. 4) .
Functional outcomes of dysferlin deficiency in skeletal muscle
Development of a clinically relevant therapeutic requires preclinical efficiency with functional outcome measures. We have previously demonstrated the use of a membrane repair assay for the FDB and specific force measurements in the diaphragm as physiological outcome measures. 16 
Membrane repair
We next evaluated the ability of AAVrh.74.DYSF.DV to improve muscle fiber membrane repair ability in dysferlin deficient muscle. We performed a membrane wounding/ resealing assay using a multiphoton laser scanning microscope on fibers isolated from the FDB. The experimental design allowed for blinding of the samples during the membrane repair assay to reduce any potential for bias. We tested FDBs from Dysf À/À mice treated by IM injection and from BlaJ mice treated by systemic delivery (described above). Dysf À/À mice at 8 weeks of age were injected IM with escalating doses of AAVrh.74.DYSF.DV (6 9 10 9 , 2 9 10 10 , and 6 9 10 10 vg total dose) in the FDB. A control Dysf À/À cohort received saline and 129-WT mice served as strain specific normal controls. Animals were sacrificed 12 weeks after injections and FDBs were isolated and processed with collagenase to isolate individual fibers. Sarcolemmal damage was induced in isolated fibers using a multiphoton laser (20% power for 5 sec) in the presence of FM1-43 dye. A small area of fluorescence was detected for all fibers immediately after laser injury at the site of damage. In WT fibers, the fiber undergoes a normal repair process and the membrane is resealed halting the influx of dye. In dysferlin deficient fibers, this repair process is altered, hindering the ability of the membrane to reseal, and thereby allowing a continuous influx of dye. Expression of dysferlin from AAVrh.74.DYSF.DV-transduced fibers resulted in a dosedependent improvement in resealing capacity (Fig. 5 ).
For the three treatment groups, only the high dose (6 9 10 10 vg) restored repair to near WT levels (ANOVA). Parallel expression studies show high dose fiber transduction of 87 AE 5.6% (not shown).
The above work was repeated for FDBs extracted from systemically treated BlaJ mice (total doses of 2 9 10 12 and 6 9 10 12 vg). Again, individual muscle fibers were isolated and wounded using a multiphoton laser in the presence of FM1-43 dye. A dose-dependent response in resealing capability was observed, with the high dose (6 9 10 12 vg) treated fibers showing repair not significantly different than WT. The low dose treatment (2 9 10 12 vg) did not differ from untreated BlaJ (Fig. 6A ).
Diaphragm physiology
Diaphragm strips from 3 month old BlaJ mice treated with saline, 2 or 6 9 10 12 vg total dose of AAVrh.74.-DYSF.DV systemically were dissected with rib attachments and central tendon intact. A 1-2 mm wide section (from rib to tendon) of diaphragm was isolated and attached to a force transducer. Following stretching the muscle to optimal length for twitch contractions, the strip was subjected to a protocol of six tetanic contractions at 2 min intervals, each with duration of 250 msec to measure specific force. All measurements were normalized to cross-sectional area. Treated diaphragms exhibited significant improvement in force (ANOVA P < 0.01), which was not different from WT force at both doses (Fig. 6B) .
Taken together, the diaphragm physiology and membrane repair data show that the large, potentially therapeutic dysferlin cDNA can be delivered to muscle and There was no significant improvement at low dose, however, high dose treatment restored repair to near wild-type levels (no significant difference). Error bars represent standard error mean. (B) Specific force generated by diaphragm muscle strips. Treated diaphragms demonstrated significant improvement in force (**P < 0.01, ANOVA) as compared to uninjected/untreated controls. Treated diaphragms were not statistically different from wild-type force at either dose.
efficiently express full-length, functional dysferlin using a dual-vector AAVrh.74 strategy.
AAV.DYSF gene transfer in NHPs
Translationally, it is important to apply the preclinical findings from work in mice to a clinical paradigm. As such, NHP offer a model with anatomic parallels to humans for safety and dosing considerations. We studied the effect of 5 9 10 12 vg total dose delivered by IM injection to the left TA of both AAV5.DYSF (n = 3) and AAVrh.74.DYSF.DV (n = 2). Saline injected right TA in the same animal served as a normal control. This dose was proportional (based on animal weight) to that given to mice. Baseline chemistries and immunological studies were performed, including ELISpot analysis to measure T cells against AAV5 and AAVrh.74 capsid and dysferlin as well as anti-AAV antibody titers (ELISA). These studies were repeated every 2 weeks for the entire study. Animals were euthanized 3 or 6 months following treatment for a full necropsy. Tissues were collected for gene expression studies including histopathology and biodistribution studies on vital organs. In both animal cohorts, the gene delivery resulted in robust expression of dysferlin in the injected muscle as compared to uninjected control (Fig. 7) . Importantly, no toxicity was seen at the tissue level in the NHPs with a lack of inflammation or muscle fiber necrosis. For AAV5.DYSF injected TAs, the muscles demonstrated 104.9% (3 months) and 122.6% (6 months) overexpression of dysferlin while AAVrh.74.DV injected TAs had 122.0% (3 months) and 115.2% (6 months) overexpression as compared to the uninjected control. Immunological assays did not show any aberrant responses to the capsid or transgene by ELISpot (Fig. S3) or ELISA (Table S1 ). In addition full CBC and chemistry panels showed no abnormal values in any of the macaques.
Discussion
AAV-mediated gene therapy presents a desirable treatment strategy for multiple diseases; however, it is hindered by the restrictive 4.7 kb packaging limit of the AAV virion. Of particular interest are diseases with no current cure or effective therapy, such as dysferlinopathies. The work here provides proof that codelivery of two vectors allows for in vivo recombination events and production of full-length, functional dysferlin. Although there is discussion in the field as to the exact mechanism of dual vector treatments (i.e. repair vs. homologous recombination), our work with AAV5.DYSF, 16 and that of others, 29, 37, 38 points to homologous recombination of partially packaged genomes as the mechanism responsible for the generation of full-length transcripts. Work by Lostal et al. with designed splicing dual vectors showed low levels (1-4%) of dysferlin expression following systemic delivery of 4 9 10 12 vg. 46 Here, we present similar levels of dysferlin expression (2-6%) following systemic delivery of 2 9 10 12 vg indicating comparable efficiency between the two methods. Importantly, a threefold increase in dose dramatically improved expression levels (15-27%) and corresponding functional improvement. Additionally, comparison of AAV5.DYSF and AAVrh.74.-DYSF.DV expression in mice revealed an increase in dysferlin expression through the dual vector delivery. Regardless of mechanism, dual vectors utilizing either strategy are becoming a viable option for expression cassettes outside the traditional packaging limit of AAV.
Importantly, the work by Lostal et al. demonstrated the potential for DYSF gene replacement through a dual vector strategy. 46 Although they were only able to demonstrate low levels of dysferlin expression, this still resulted in an improvement in muscle pathology as well as an improvement in membrane repair. In their work, the low levels of dysferlin expression were not sufficient to restore functional measures to WT levels which led them to postulate that levels of 30% dysferlin expression would be necessary for clinically meaningful outcomes. 46 Following this work, we tested both low (2 9 10 12 vg) and high (6 9 10 12 vg) systemic doses of AAVrh.74.DYSF.DV leading to 2-6% and 15-27% dysferlin expression respectively. Functional outcome measures in membrane repair and diaphragm specific force were restored to WT levels for the high dose, suggesting that lower levels of expression (~25%) may be sufficient to see a clinical benefit. This is corroborated by considering carriers of DYSF mutations which have no clinical symptoms of dysferlinopathy but with <50% dysferlin protein expression. 47 After demonstration of robust, wide-spread expression of dysferlin in mouse models, we moved the dual vector treatment strategy into rhesus macaques to study the efficacy and safety of such a therapy. Rhesus macaques and other NHPs have been used extensively as an approximation to a human response due to anatomic similarities. 25, [48] [49] [50] [51] [52] [53] As such, we studied not only the expression of dysferlin delivered by gene therapy, but also the systemic immunological response in the primates. Monitoring an immune response was critical as previous work demonstrated toxicity and progressive myopathy in cases of transgene overexpression. 39 In addition, previous work has shown that pre-existing immunity to the vector capsid results in diminished to absent expression of the transgene. 48 Thus, primates were prescreened prior to treatment for circulating binding antibodies to AAVrh.74, with only primates negative for AAV antibodies used for the study. We found that AAVrh.74.DYSF.DV treatment in macaque skeletal muscle can stimulate the overexpression of dysferlin with no apparent toxicity or systemic immune rejection, laying a foundation for preclinical safety. Potential immune responses were carefully monitored through both serum ELISAs and PBMCs ELISpot assays. Peptide pools used to stimulate the PBMCs were designed to be 15 amino acids long, overlapping by 10 amino acids so as to capture all possible antigenic epitopes. The lack of immune response shown in all of the primates is therefore encouraging. Our dose level led to thorough transduction of the treated muscle, which will guide our future toxicology studies as we prepare for clinical trial. A formal pre-IND discussion with the FDA (L. R. Rodino-Klapac and J. R. Mendell, pers. comm.) defined a potential path for a dysferlin dual vector clinical gene therapy trial providing no problems are encountered in planned toxicology/biodistribution studies done with the same rigor as other approved AAV vectors. [54] [55] [56] In conclusion, our dual vector work is a promising therapeutic strategy for the treatment of dysferlinopathy aberrant protein production. Furthermore, the success of multiple routes of delivery provides the option to vary treatment according to clinical presentation. The IM targeted therapy allows for the treatment of individual muscle groups affected in MM1 and distal anterior compartment myopathy, while the vascular and systemic delivery methods can be useful for gene delivery treatment of muscle compartments relevant to LGMD2B or MM1.
